A method for constructing an animal model of non-small cell lung cancer and its application

By co-cultivating the conditional fluid culture of human lung cancer fibroblasts and bone marrow mesenchymal stem cells, the subcutaneous injection technology of A549 cells was optimized, and the problems of long construction time and low modeling rate of non-small cell lung cancer animal models were solved, achieving rapid development Model and high success rate tumor model construction.

CN118661688BActive Publication Date: 2024-11-22GUANGZHOU BOJI MEDICINE SERVICES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410907510.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-08
Publication Date
2024-11-22
Estimated Expiration
2044-07-08

AI Technical Summary

Technical Problem

The existing non-small cell lung cancer animal model has a long construction time and a low modeling rate, which leads to slow tumor growth, which may be due to slow tumor cell proliferation, unsuitable growth conditions at the transplant site, insufficient cell inoculation or low survival rate.

Method used

By co-culturing human lung cancer fibroblasts and human bone marrow mesenchymal stem cells, the conditioned co-culture medium was collected, and A549 cells were used to culture A549 cells to form a suspension, and subcutaneously inject them to construct an animal model of non-small cell lung cancer and optimize tumor cell inoculation and inoculation techniques.

Benefits of technology

The tumor volume reached 117.33±11.28mm3 within 7 days, with a modeling success rate of 100%, with a small amount of tumor cells required, a short modeling cycle and a high success rate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118661688B_ABST
    Figure CN118661688B_ABST
Patent Text Reader

Abstract

The present invention provides a method for constructing an animal model of non-small cell lung cancer and its application, belonging to the field of biomedical technology. The method for constructing an animal model of non-small cell lung cancer provided by the present invention comprises the following steps: S1, after co-culturing human lung cancer fibroblasts and human bone marrow mesenchymal stem cells, collecting the supernatant, filtering, and obtaining a conditioned co-culture solution; S2, culturing A549 cells with a culture medium containing the conditioned co-culture solution to obtain an A549 cell suspension; S3, subcutaneously injecting the A549 cell suspension into an animal to obtain an animal model of non-small cell lung cancer. The animal model of non-small cell lung cancer is constructed by the construction method provided by the present invention, and 1×10 6 On the 7th day after the inoculation of A549 cells, the tumor volume reached 117.33±11.28mm 3 The construction method provided by the present invention requires a small amount of tumor cells to be inoculated, a short modeling period and a high modeling success rate.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a method for constructing a non-small cell lung cancer animal model and its application. Background Art

[0002] Lung cancer is one of the malignant tumors with high morbidity and mortality worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 80%-85% of the total number of lung cancers. Its treatment and research face many challenges. The occurrence of NSCLC is a complex process with multiple steps and multiple factors, with significant tumor heterogeneity, including different pathological subtypes, gene mutation spectra and immune phenotypes. In the field of lung cancer research, animal models are of irreplaceable importance for in-depth understanding of the pathogenesis of lung cancer, exploring treatment strategies and evaluating drug efficacy. By constructing animal models, the entire dynamic process from precancerous lesions to tumor formation, progression and metastasis can be reproduced, which helps to reveal the interaction between tumor cells and the microenvironment, as well as the mechanism of action of gene mutations in the occurrence of the disease. The generation and evolution of this heterogeneity can be studied in the in vivo environment, providing a theoretical basis for personalized treatment.

[0003] In heterotopic transplantation, subcutaneous implantation in the back or armpit is a common method. Since tumor models are easy to construct and test, the size and location of the tumor can be easily controlled, individual differences are small, the effects on the host are similar, and the efficacy can be easily and objectively judged, they have been widely used in the construction of animal tumor models. However, in practical applications, the long time and low success rate of animal tumor model construction have always been key factors restricting the progress of related research, which may be caused by the following reasons: (1) The transplanted tumor cells themselves have a relatively slow proliferation rate. (2) The heterotopic transplantation site may not provide the same suitable growth conditions as the primary tumor site, such as differences in nutrient supply, cell-cell interactions, angiogenesis, etc., resulting in slow tumor growth. (3) Insufficient number of inoculated tumor cells or low cell survival rate during inoculation can also lead to prolonged tumor formation time.

[0004] The key to solving the above problems is to select tumor cell lines with high proliferation and invasion ability for transplantation; to pre-treat tumor cells before transplantation, such as adding growth factors or cytokines in culture to create a microenvironment conducive to the rapid growth of tumor cells; and to improve cell inoculation technology. Therefore, providing a method for constructing a new non-small cell lung cancer animal model with a short modeling cycle and high modeling rate plays an important role in the study of tumor biological mechanisms, drug development, and treatment strategy evaluation, and brings hope for improving the treatment effect and prognosis of NSCLC patients. Summary of the invention

[0005] In view of the above shortcomings, the present invention provides a method for constructing an animal model of non-small cell lung cancer and its application. The method for constructing an animal model of non-small cell lung cancer provided by the present invention comprises the following steps: S1, after co-culturing human lung cancer fibroblasts and human bone marrow mesenchymal stem cells, collecting the supernatant, filtering, and obtaining a conditioned co-culture solution; S2, culturing A549 cells with a culture medium containing the conditioned co-culture solution to obtain an A549 cell suspension; S3, subcutaneously injecting the A549 cell suspension into an animal to obtain an animal model of non-small cell lung cancer. The animal model of non-small cell lung cancer is constructed using the construction method provided by the present invention, and 1×10 6 On the 7th day after the inoculation of A549 cells, the tumor volume reached 117.33±11.28mm 3 The construction method provided by the present invention requires a small amount of tumor cells to be inoculated, a short modeling period and a high modeling success rate.

[0006] To achieve the above purpose, the technical solution provided by the present invention is as follows:

[0007] In one aspect, the present invention provides a method for constructing an animal model of non-small cell lung cancer, the method comprising the following steps:

[0008] S1. After co-culturing human lung cancer fibroblasts and human bone marrow mesenchymal stem cells, the supernatant was collected and filtered to obtain a conditioned co-culture solution;

[0009] S2, culturing A549 cells with a culture medium containing a conditioned co-culture medium to obtain an A549 cell suspension;

[0010] S3. Inject the A549 cell suspension subcutaneously into the animal to obtain a non-small cell lung cancer animal model.

[0011] Specifically, the inoculation ratio of human lung cancer fibroblasts to human bone marrow mesenchymal stem cells in step S1 is 1:3-5.

[0012] Preferably, the inoculation ratio of human lung cancer fibroblasts to human bone marrow mesenchymal stem cells in step S1 is 1:4.

[0013] Specifically, the co-culture culture medium described in step S1 is a culture medium containing FBS, double antibody, laminin, fibroblast growth factor FGF-2, L-glutamine, L-leucine, vitamin B12, and vitamin E.

[0014] Preferably, the co-culture culture medium described in step S1 is a DMEM culture medium containing 10%-20% FBS, 1%-3% double antibody, 2.5-7.5 mg / L laminin, 0.03-0.09 mg / L fibroblast growth factor FGF-2, 300-500 mg / L L-glutamine, 25-75 mg / L L-leucine, 10-20 mg / L vitamin B12, and 15-20 mg / L vitamin E.

[0015] Further preferably, the co-culture culture medium described in step S1 is a DMEM culture medium containing 10% FBS, 1% double antibody, 5 mg / L laminin, 0.06 mg / L fibroblast growth factor FGF-2, 400 mg / L L-glutamine, 50 mg / L L-leucine, 15 mg / L vitamin B12, and 17.5 mg / L vitamin E.

[0016] Specifically, the co-culture conditions in step S1 are 5% CO2, 35-39°C cell culture incubator for 24-96 hours.

[0017] Preferably, the co-culture conditions in step S1 are 5% CO2, 37°C cell culture incubator for 48 hours.

[0018] Specifically, the supernatant collected in step S1 is collected by centrifuging at 3000 rpm for 10 min.

[0019] Specifically, the filtration described in step S1 is 0.22 μm filter membrane filtration.

[0020] Specifically, the culture medium in step S2 is a culture medium containing 60%-70% conditioned co-culture solution.

[0021] Preferably, the culture medium in step S2 is a culture medium containing 60%-70% conditioned co-culture solution.

[0022] Preferably, the culture medium described in step S2 includes but is not limited to F-12K culture medium, DMEM culture medium, and RPMI-1640 culture medium.

[0023] Further preferably, the culture medium in step S2 is DMEM culture medium.

[0024] Specifically, the A549 cells described in step S2 are A549 cells that have been passaged for more than 15 generations.

[0025] Specifically, the method for culturing A549 cells in step S2 is: inoculating A549 cells in a culture medium, replacing fresh culture medium every 24 hours, and culturing for 96 hours.

[0026] Preferably, the culture conditions for culturing A549 cells in step S2 are 5% CO2 and 35-39°C.

[0027] More preferably, the culture conditions for culturing A549 cells in step S2 are 5% CO2 and 37°C.

[0028] Specifically, the cell concentration of the A549 cell suspension described in step S2 is 1×10 6 / mL-1×10 8 Pieces / mL.

[0029] Preferably, the cell concentration of the A549 cell suspension in step S2 is 5×10 6 Pieces / mL.

[0030] Specifically, the injection volume of the A549 cell suspension described in step S3 was ≥ 1 × 10 6 indivual.

[0031] Preferably, the injection volume of the A549 cell suspension in step S3 is 1×10 6 indivual.

[0032] Specifically, the animals described in step S3 include but are not limited to mice, rats, zebrafish, dogs, rabbits or monkeys.

[0033] Preferably, the animals described in step S3 include but are not limited to C57BL mice, BALB / c, DBA mice, C3H / He mice, nude mice, NOD-SCID mice, and Kunming mice.

[0034] More preferably, the animal in step S3 is a BALB / c nude mouse.

[0035] Still more preferably, the animals in step S3 include 4-8 week old BALB / c nude mice.

[0036] More preferably, the animal in step S3 is a 4-week-old BALB / c nude mouse.

[0037] On the other hand, the present invention provides a non-small cell lung cancer animal model constructed by the above construction method.

[0038] In another aspect, the present invention provides the use of the above construction method and the above non-small cell lung cancer animal model in any of the following aspects:

[0039] (1) Study the pathogenesis of non-small cell lung cancer; or

[0040] (2) Research on treatments for non-small cell lung cancer; or

[0041] (3) Screening for drugs or vaccines to prevent or treat non-small cell lung cancer; or

[0042] (4) Test drug safety and effectiveness.

[0043] Compared with the prior art, the present invention has the following beneficial effects:

[0044] The animal model of non-small cell lung cancer was constructed by the construction method provided by the present invention, and 1×10 6 On the 7th day after the inoculation of A549 cells, the tumor volume reached 117.33±11.28mm 3 The construction method provided by the present invention requires a small amount of tumor cells to be inoculated, a short modeling period and a high modeling success rate. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 This is the tumor volume growth curve of mice with non-small cell lung cancer. DETAILED DESCRIPTION

[0046] The present invention will be further described in detail below by way of examples. The following examples are only a part of the present invention and are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are not specifically stated, and the materials, reagents, etc. used in the following examples are all commercially available unless otherwise specified.

[0047] The experimental materials used in the present invention are shown in Table 1:

[0048] Table 1 Experimental materials

[0049] name factory Part Number A549 cells Wuhan Prosai Life Science Co., Ltd. CL-0016 Human lung cancer fibroblasts Wuhan Prosai Life Science Co., Ltd. CP-H245 Human bone marrow mesenchymal stem cells Wuhan Prosai Life Science Co., Ltd. CP-H166 Complete medium for human lung cancer fibroblasts Wuhan Prosai Life Science Co., Ltd. CM-H245 Complete medium for human bone marrow mesenchymal stem cells Wuhan Prosai Life Science Co., Ltd. CM-H166

[0050] Basic Experimental Example 1 Preparation of Conditioned Culture Medium of Human Lung Cancer Fibroblasts and Human Bone Marrow Mesenchymal Stem Cells

[0051] 1. Culture of human lung cancer fibroblasts:

[0052] (1) Take out the frozen human lung cancer fibroblasts and quickly thaw them in a 37°C water bath. Then transfer the cell suspension to a centrifuge tube, add an appropriate amount of complete medium for human lung cancer fibroblasts, mix gently, centrifuge at 1000 rpm for 5 minutes, discard the supernatant, add complete medium for human lung cancer fibroblasts to resuspend the cells, inoculate them into culture bottles, and place them in a 37°C, 5% CO2 incubator for culture.

[0053] (2) When the cells grow to a confluence of about 80-90%, subculture. Aspirate the old culture medium in the culture bottle, wash the cells twice with PBS, add an appropriate amount of trypsin digestion solution, place in a 37°C incubator for digestion for 1-2 minutes, observe the cell morphology under a microscope, and when the cells become round and shrink, add an appropriate amount of human lung cancer fibroblast complete culture medium to terminate the digestion. Gently blow the cells to detach them from the bottom of the culture bottle, transfer the cell suspension to a centrifuge tube, centrifuge at 1000rpm for 5 minutes, discard the supernatant, add human lung cancer fibroblast complete culture medium to resuspend the cells, and subculture at a ratio of 1:3, subculture once every 3-4 days; the cells used in the experiment are the third generation cells.

[0054] 2. Culture of human bone marrow mesenchymal stem cells:

[0055] Human bone marrow mesenchymal stem cells were cultured and passaged in a 37°C, 5% CO2 incubator using complete culture medium for human bone marrow mesenchymal stem cells. The operation method was referred to "Cultivation of human lung cancer fibroblasts".

[0056] 3. A549 cell culture:

[0057] The A549 cell culture and subculture method refers to "Human lung cancer fibroblast culture". The cells are cultured in a 37°C, 5% CO2 incubator with DMEM complete medium containing 10% FBS and 1% double antibody. When the cells grow to a confluence of about 80-90%, they are subcultured once every 3 days. After the 5th generation, the cells are subcultured once a day, and the A549 cells after the 15th generation are used for experiments.

[0058] Example 1 Preparation of Conditioned Culture Medium of Human Lung Cancer Fibroblasts and Human Bone Marrow Mesenchymal Stem Cells

[0059] Human lung cancer fibroblasts (1×10 5 / well) and human bone marrow mesenchymal stem cells (4×10 5 The cells were co-inoculated with 10% FBS, 1% double antibody, 5 mg / L laminin, 0.06 mg / L fibroblast growth factor FGF-2, 400 mg / L L-glutamine, 50 mg / L L-leucine, 15 mg / L vitamin B12, and 17.5 mg / L vitamin E in a 12-well plate, and cultured in a 5% CO2, 37°C cell culture incubator for 48 h. The supernatant was collected by centrifugation at 3000 rpm for 10 min, and filtered through a 0.22 μm filter membrane to obtain a conditioned medium.

[0060] Example 2 Preparation of A549 cell suspension

[0061] A549 cells in the logarithmic growth phase were taken and 5×10 5Cells were inoculated into 6-well plates containing 65% conditioned medium in DMEM complete medium. Fresh medium was replaced every 24 hours. After 96 hours of culture at 5% CO2 and 37°C, the medium was discarded and the cells were washed twice with PBS. An appropriate amount of trypsin was added for digestion. After the cells became round and detached from the wall, the serum-containing medium was added to terminate the digestion. The cell suspension was transferred to a centrifuge tube and centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded. The cells were resuspended in PBS and counted. The cell concentration was adjusted to 5×10 6 / mL to obtain A549 cell suspension.

[0062] Example 3 Construction of animal model of non-small cell lung cancer

[0063] In this example, 4-week-old BALB / c male nude mice were used to construct a non-small cell lung cancer model. BALB / c nude mice were raised in a sterile environment and adapted to the environment for 1 week. The mice were weighed before surgery, and the inoculation site of the mice was disinfected with iodine. 200 μL of the A549 cell suspension prepared in Example 2 was drawn with a 1 mL syringe and slowly injected subcutaneously on the side of the mouse back. After inoculation, the injection site was gently pressed to avoid overflow of the cell suspension.

[0064] After tumor cell inoculation (denoted as D1), starting from the fifth day, the growth of subcutaneous transplanted tumors in nude mice was observed every 2 days. The long diameter (a) and short diameter (b) of the tumor were measured with a vernier caliper every day, and the tumor volume (V = 1 / 2 × a × b 2 The results are shown in Table 2 and Figure 1 .

[0065] Table 2 Tumor volume (mm) of animal models of non-small cell lung cancer 3 , n=5)

[0066] Days Mean SD D5 43.48 6.34 D7 117.33 11.28 D9 235.77 15.15 D11 419.36 31.09 D13 761.70 75.99 D15 1383.60 83.94 D17 2102.68 156.23

[0067] In general, subcutaneous transplant models are established when the tumor volume reaches 50-200 mm 3 The model was considered to be initially successful when the tumor reached 100 mm. 3 The experiment was then started. The measurement results showed that the tumor volume of the non-small cell lung cancer animal model provided by the present invention reached 117.33±11.28mm on the 7th day after tumor cell inoculation. 3 , meeting the modeling success criteria.

[0068] Comparative Example 1: Preparation of A549 cell suspension using human lung cancer fibroblast conditioned medium

[0069] 1. Preparation of Conditioned Culture Medium of Human Lung Cancer Fibroblasts

[0070] Human lung cancer fibroblasts (1×105 The cells were inoculated into a 12-well plate containing 10% FBS, 1% double antibody, 5 mg / L laminin, 0.06 mg / L fibroblast growth factor FGF-2, 400 mg / L L-glutamine, 50 mg / L L-leucine, 15 mg / L vitamin B12, and 17.5 mg / L vitamin E in a DMEM medium, and cultured in a 5% CO2, 37°C cell culture incubator for 48 h. The supernatant was collected by centrifugation at 3000 rpm for 10 min, and filtered through a 0.22 μm filter membrane to obtain a conditioned medium.

[0071] 2. Preparation of A549 cell suspension

[0072] The preparation of A549 cell suspension was the same as that in “Preparation of A549 cell suspension in Example 2”.

[0073] Comparative Example 2: Preparation of A549 cell suspension using human bone marrow mesenchymal stem cell conditioned medium

[0074] 1. Preparation of human bone marrow mesenchymal stem cell conditioned medium

[0075] Human bone marrow mesenchymal stem cells (4×10 5 The cells were co-inoculated into a 12-well plate containing 10% FBS, 1% double antibody, 5 mg / L laminin, 0.06 mg / L fibroblast growth factor FGF-2, 400 mg / L L-glutamine, 50 mg / L L-leucine, 15 mg / L vitamin B12, and 17.5 mg / L vitamin E in a DMEM medium, and cultured in a 5% CO2, 37°C cell culture incubator for 48 h. The supernatant was collected by centrifugation at 3000 rpm for 10 min, and filtered through a 0.22 μm filter membrane to obtain a conditioned culture medium.

[0076] 2. Preparation of A549 cell suspension

[0077] The preparation of A549 cell suspension was the same as that in “Preparation of A549 cell suspension in Example 2”.

[0078] Comparative Example 3DMEM medium was used to prepare the conditioned medium for the preparation of A549 cell suspension

[0079] 1. Preparation of Conditioned Medium

[0080] Human lung cancer fibroblasts (1×10 5 / well) and human bone marrow mesenchymal stem cells (4×10 5The cells were inoculated into a 12-well plate containing 10% FBS and 1% double antibody in a DMEM medium and cultured in a 5% CO2, 37°C cell culture incubator for 48 h. The supernatant was collected by centrifugation at 3000 rpm for 10 min and filtered through a 0.22 μm filter membrane to obtain a conditioned medium.

[0081] 2. Preparation of A549 cell suspension

[0082] The preparation of A549 cell suspension was the same as that in “Preparation of A549 cell suspension in Example 2”.

[0083] Comparative Example 4 Preparation of A549 cell suspension

[0084] A549 cells in the logarithmic growth phase were taken and 5×10 5 Cells were inoculated into 6-well plates with complete DMEM medium at 1000 cells / well. Fresh medium was replaced every 24 hours. After 96 hours of culture at 5% CO2 and 37°C, the medium was discarded and the cells were washed twice with PBS. An appropriate amount of trypsin was added for digestion. After the cells became round and detached from the wall, serum-containing medium was added to terminate the digestion. The cell suspension was transferred to a centrifuge tube and centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded. The cells were resuspended in PBS and counted. The cell concentration was adjusted to 5×10 6 / mL to obtain A549 cell suspension.

[0085] Experimental Example 1 Effect of the A549 cell suspension prepared in Comparative Examples 1-4 on tumor volume

[0086] BALB / c nude mice were raised in a sterile environment and adapted to the environment for 1 week. The mice were weighed before surgery, and the inoculation site of the mice was disinfected with iodine. 200 μL of the A549 cell suspension prepared in Comparative Example 1-4 was drawn with a 1 mL syringe and slowly injected subcutaneously on the side of the mouse back. After inoculation, the injection site was gently pressed to prevent the cell suspension from overflowing.

[0087] After tumor cell inoculation (denoted as D1), starting from the fifth day, the growth of subcutaneous transplanted tumors in nude mice was observed every 2 days. The long diameter (a) and short diameter (b) of the tumor were measured with a vernier caliper every day, and the tumor volume (V = 1 / 2 × a × b 2 The results are shown in Tables 3 and Figure 1 .

[0088] Table 3 Comparative Examples 1-4 Non-small cell lung cancer animal model tumor volume (mm 3 , n=5)

[0089]

[0090] From the above results, it can be seen that the tumor volume of comparative example 1 on the 9th day after tumor inoculation was 68.66±6.20mm 3 On the 7th day after tumor inoculation, the tumor volume of Comparative Example 2 and Comparative Example 3 reached 50 mm 3 Above, but the tumor volume did not reach 65mm 3 In comparative example 4, the diameter of the tumor was 60.04±10.30 mm on the 11th day after tumor inoculation. 3 The tumor volume reached 151.77 mm on the 13th day. 3 of tumor volume.

[0091] Experimental Example 2 Modeling success rate of Example 2

[0092] Different batches (3 batches, 10 mice per batch) of BALB / c nude mice were raised in a sterile environment and adapted to the environment for 1 week. The mice were weighed before surgery, and the inoculation site of the mice was disinfected with iodine. 200 μL of the A549 cell suspension prepared in Example 2 was drawn with a 1 mL syringe and slowly injected subcutaneously on the side of the mouse back. After inoculation, the injection site was gently pressed to avoid overflow of the cell suspension.

[0093] According to Table 2 and Table 3, Example 2 was modeled on the 7th day. Therefore, after tumor cell inoculation (recorded as D1), the long diameter (a) and short diameter (b) of the tumor were measured with a vernier caliper on the 7th day, and the tumor volume (V = 1 / 2 × a × b2) was calculated and recorded. Tumor volume ≥ 100 mm 3 The modeling is successful.

[0094] Table 4 Tumor volume of each batch of non-small cell lung cancer animal models (mm 3 )

[0095] Mouse number Batch 1 Batch 2 Batch 3 1 133.888 124.4853 118.1123 2 104.4927 127.5787 143.2215 3 135.507 116.0299 120.0518 4 149.9046 143.0963 103.0576 5 143.1391 126.1723 131.3528 6 108.6872 135.2287 137.779 7 119.8129 149.9013 107.7711 8 132.3939 110.3543 119.956 9 107.4435 121.9452 116.6244 10 121.0219 125.3367 123.3936 Mean 125.6291 128.0129 122.132 SD 15.73035 11.89816 12.48035 Molding rate 100% 100% 100%

[0096] The results showed that the non-small cell lung cancer model was constructed by the method provided by the present invention in three different batches of BALB / c nude mice, and the success rate was 100%. On the 7th day after the tumor was inoculated, the tumor volume of the three batches of mice was 100-150mm 3 The reproducibility is good.

[0097] The above detailed description is a specific description of one of the feasible embodiments of the present invention, and the embodiment is not intended to limit the scope of the present invention. It should be pointed out that any equivalent implementation or change that does not deviate from the present invention should be included in the scope of the technical solution of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached requirements.

Claims

1. A method for constructing an animal model of non-small cell lung cancer, characterized in that: The construction method comprises the following steps: S1. After co-culturing human lung cancer fibroblasts and human bone marrow mesenchymal stem cells, the supernatant was collected and filtered to obtain a conditioned co-culture solution; S2, culturing A549 cells with a culture medium containing a conditioned co-culture medium to obtain an A549 cell suspension; S3. Inject the A549 cell suspension subcutaneously into the animal to obtain a non-small cell lung cancer animal model.

2. The construction method according to claim 1, characterized in that: The inoculation ratio of human lung cancer fibroblasts and human bone marrow mesenchymal stem cells described in step S1 is 1:

4.

3. The construction method according to claim 1, characterized in that: The co-culture medium described in step S1 is a medium containing FBS, double antibody, laminin, fibroblast growth factor FGF-2, L-glutamine, L-leucine, vitamin B12 and vitamin E.

4. The construction method according to claim 3, characterized in that: The co-culture medium described in step S1 is a DMEM medium containing 10% FBS, 1% double antibody, 5 mg / L laminin, 0.06 mg / L fibroblast growth factor FGF-2, 400 mg / L L-glutamine, 50 mg / L L-leucine, 15 mg / L vitamin B12 and 17.5 mg / L vitamin E.

5. The construction method according to claim 1, characterized in that: The culture medium described in step S2 is a culture medium containing 60%-70% conditioned co-culture solution.

6. The construction method according to claim 5, characterized in that: The culture medium described in step S2 is a culture medium containing 65% conditioned co-culture solution.

7. The construction method according to claim 1, characterized in that: The injection volume of A549 cell suspension described in step S3 is ≥ 1 × 10 6 indivual.

8. The construction method according to claim 1, characterized in that: The animal described in step S3 is a mouse.

9. Application of the construction method according to any one of claims 1 to 8 in any of the following aspects: (1) Study the pathogenesis of non-small cell lung cancer; or (2) Research on treatments for non-small cell lung cancer; or (3) Screening for drugs or vaccines to prevent or treat non-small cell lung cancer; or (4) Testing drug safety and efficacy.